Just like China wants Trump to lose the US presidential poll, it may want Modi to lose the Lok Sabha polls. So months before the 2024 elections, China may take possession of an important area, say one of the Char Dhams, warns Sanjeev Nayyar.
Whistle-blower Dinesh Thakur will speak on Made-in-India drugs at an event in Washington.
Credit Suisse analysts cut their rating on Sun Pharma stock to 'neutral' from 'outperform
India's IPR framework and enforcement were comparable to those in developed countries
Ministerial consultations on, with recognition of the potential, and the need to not classify it under the same rules as for pharmaceuticals.
Bharti Airtel , RCom and Tata Communications ended down between 0.1-1%.
'Unless cash has ceased to be king, the issue is the same in the aviation, telecom and ecommerce sectors: Sustainability,' notes T N Ninan.
Margaret A Hamburg, the first commissioner of the US Food and Drug Administration (US FDA) to visit India officially, will meet heads of major domestic pharma companies such as Ranbaxy, Wockhardt, Cadila Healthcare and Lupin in New Delhi.
Next week, US Secretary of State John Kerry travels to India for the fourth annual US-India Strategic Dialogue
Infosys, Wipro and HUL among the top losers for the day.
Dhirubhai Ambani lived in a one-room chawl in Mumbai with his wife and children and went on to establish the Reliance Group.
It is domestic policy distortions and inaction to correct them that lie behind the large CADs.
Oil and gas sectot may not put up good numbers in Q4.
The Indian government headed by Prime Minister Manmohan Singh, who is known as the architect of the country's liberalisation and economic reforms, is inching towards a "protectionist" regime, top American experts have told US lawmakers.
'Only when China treats India as an equal can we consider them real friends.'
If currency controls are maintained indefinitely, popular support for Narendra Modi's demonetisation will turn into dislike, warns Devangshu Datta.
With EU, it is part of the FTA that we will need to negotiate.
Over the past four quarters, the Sensex companies' earnings trajectory has improved sharply because of a weak rupee.
'Experts are not ruling out further pain as global factors cannot insulate India from the aftermath.'
Markets across the globe are rallying on hopes that the US Federal Reserve won't lift interest rates until 2016.
'It is not that the H1B visa employees are coming in to displace jobs.'
Earnings growth is unlikely to see much recovery and sales revenues are also likely to remain muted
India may not be prepared to meet US demands, say experts
The S&P BSE Sensex has dipped five per cent, thus far, in CY15.
'The boycott has not achieved success. Sales figures for Chinese products on the top three Indian online retailers in the first week of October hit a new record. Amazingly, the Chinese mobile phone company Xiaomi sold half a million phones in just three days on the Flipkart, Amazon India, Snapdeal and Tata CLiQ platforms.'
'The failures of private businessmen have set back the process of market-oriented reform, though that is the only way forward,' argues T N Ninan.
.jpg)
India has been pursuing measures that discriminate against overseas businesses, says US Congressman Erik Paulsen.
FDA had cancelled Ranbaxy's approvals to launch generic Nexium, Valcyte
market, was today seized from an illegal drug manufacturing unit in Jalgaon district in north Maharashtra and six persons were arrested, Directorate of Revenue Intelligence officials said.
Benchmark indices finished higher on hopes of economic reforms
Wockhardt MD Murtaza Khorakiwala said his firm had responded to the FDA's observations but declined to give details.
The S&P BSE Sensex dropped 207 points to end at 25,230.
President Xi said that the Chinese side is ready to work with the Indian side to carry forward the fresh impetus of bilateral relations.
The industry feels that prices of active pharmaceutical ingredients (APIs) can go up in the range of 5-15 per cent.
The Ranbaxy experience has made multinational corporations more cautious about Indian acquisitions in general
Index heavyweight RIL surged 3% to end above Rs 1,000 mark while IT majors were also the top gainers.
Fresh guidelines were issued by the government on Wednesday for enforcing the second phase of the coronavirus lockdown, with the Union home ministry barring all kinds of public transport and prohibiting opening of public places during this period.
Financials are the top gainers along with index heavyweights.
'If we play our cards right, we may even benefit from the competition between the US and China as seen from increased investment from each of these countries into India.' 'The size of our market gives us an important lever of power which we shall have to play adroitly and intelligently,' points out Ambassador Gautam Bambawale -- who served as India's envoy to China -- in the Professor V M Dandekar Memorial Lecture 2019, delivered on March 8, 2019 in Pune.
Congress a distant second with Rs 198.16 crores.
